TY - JOUR
T1 - Impact of COVID-19 on Liver Transplant Activity in the USA
T2 - Variation by Etiology and Cirrhosis Complications
AU - Kuo, Yong Fang
AU - Kwo, Paul
AU - Wong, Robert J.
AU - Singal, Ashwani K.
N1 - Publisher Copyright:
© 2023 The Author(s).
PY - 2023/2/28
Y1 - 2023/2/28
N2 - Background and Aims: The COVID-19 pandemic has impacted the care of patients with liver disease. We ex-amined impact of COVID-19 on liver transplant (LT) activity in the USA. Methods: LT listings in the United Network for Organ Sharing (UNOS) database (April 2018–May 2021) were analyzed to examine the impact of COVID-19 pandemic on the LT activity based on etiology: hepatitis C virus (HCV), alcohol-associated liver disease (ALD), alcoholic hepatitis (AH), and nonalcoholic steatohepatitis (NASH) complications: hepatocellular carcinoma (HCC) and acute-on-chronic liver failure (ACLF) grade 2 or 3) and Model for End-Stage Liver Disease (MELD) score. Joinpoint regression models assessed time trend changes on a log scale. Results: Of 23,871 recipients (8,995 in the COV-ID era, April 2018–February 2020), mean age 52 years, 62% men, 61% Caucasian, 32% ALD, 15% HCC, 30% ACLF grades 2–3, and mean MELD score 20.5), monthly LT changes were a decrease of 3.4% for overall LTs and 22% for HCC after September 2020, and increase of 4.5% for ALD since 11/2020 and 17% since 03/2021 for ACLF grade 2–3. Monthly MELD scores increased by 0.7 and 0.36 after June 2020 for HCV and HCC respectively. Conclusions: The COVID-19 pandemic has impacted LT activity, with a decrease of LTs especially for HCC, and an increase of LTs for ALD and severe ACLF. Strategies are needed to reor-ganize cirrhosis patients to overcome the aftereffects of COVID-19 pandemic.
AB - Background and Aims: The COVID-19 pandemic has impacted the care of patients with liver disease. We ex-amined impact of COVID-19 on liver transplant (LT) activity in the USA. Methods: LT listings in the United Network for Organ Sharing (UNOS) database (April 2018–May 2021) were analyzed to examine the impact of COVID-19 pandemic on the LT activity based on etiology: hepatitis C virus (HCV), alcohol-associated liver disease (ALD), alcoholic hepatitis (AH), and nonalcoholic steatohepatitis (NASH) complications: hepatocellular carcinoma (HCC) and acute-on-chronic liver failure (ACLF) grade 2 or 3) and Model for End-Stage Liver Disease (MELD) score. Joinpoint regression models assessed time trend changes on a log scale. Results: Of 23,871 recipients (8,995 in the COV-ID era, April 2018–February 2020), mean age 52 years, 62% men, 61% Caucasian, 32% ALD, 15% HCC, 30% ACLF grades 2–3, and mean MELD score 20.5), monthly LT changes were a decrease of 3.4% for overall LTs and 22% for HCC after September 2020, and increase of 4.5% for ALD since 11/2020 and 17% since 03/2021 for ACLF grade 2–3. Monthly MELD scores increased by 0.7 and 0.36 after June 2020 for HCV and HCC respectively. Conclusions: The COVID-19 pandemic has impacted LT activity, with a decrease of LTs especially for HCC, and an increase of LTs for ALD and severe ACLF. Strategies are needed to reor-ganize cirrhosis patients to overcome the aftereffects of COVID-19 pandemic.
KW - COVID-19
KW - OLT
KW - Public policies
KW - Region
KW - UNOS
UR - http://www.scopus.com/inward/record.url?scp=85141475398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141475398&partnerID=8YFLogxK
U2 - 10.14218/JCTH.2022.00129
DO - 10.14218/JCTH.2022.00129
M3 - Article
C2 - 36406316
AN - SCOPUS:85141475398
SN - 2225-0719
VL - 11
SP - 130
EP - 135
JO - Journal of Clinical and Translational Hepatology
JF - Journal of Clinical and Translational Hepatology
IS - 1
ER -